ArticleCancers2024
Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and Immunotherapy.
Abstract read
In one paragraph
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Microbiome-Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma.International journal of molecular sciences · 2026Review
- Host-Microbiome Integration as a Biomarker Framework in Esophageal Cancer: Current Evidence and Translational Challenges.Current issues in molecular biology · 2026Review
- Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Regulation of PD-1PD-L1 Immune Checkpoints by Gut Microbiota Metabolites and Their Clinical Translational Research: A Review.Immunity, inflammation and disease · 2026Review
- Harnessing the microbiome for cancer therapy.Nature reviews. Microbiology · 2026Review
- Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential.Frontiers in microbiology · 2026Review
- Intestinal and esophageal microbiota in esophageal cancer development and treatment.Gut microbes · 2025Review
- Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention.Nature reviews. Clinical oncology · 2025Review
- Timing and Protocols for Microbiome Intervention in Surgical Patients: A Literature Review of Current Evidence.Cureus · 2025Review
- Microbial metabolites and their influence on the tumor microenvironment.Frontiers in immunology · 2025Review
- Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Fyza Y ShaikhDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Seoho LeeDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
James R WhiteResphera Biosciences, Baltimore, MD 21231, USA.ORCID 0000-0002-7535-9179
Yujie ZhaoDepartment of Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD 21218, USA.
Jacqueline T FerriDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Gavin PereiraThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Blair V LandonThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-5235-7410
Suqi KeThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Chen HuThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-4672-1981
Josephine L FelicianoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Russell K HalesThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
K Ranh VoongThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Richard J BattafaranoDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Stephen C YangDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-2188-3407
Stephen BroderickDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Jinny HaDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Elizabeth ThompsonDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Eun J ShinDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-0624-8149
David L BartlettAllegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.ORCID 0000-0003-3099-2613
Benny WekslerAllegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.
Drew M PardollDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Valsamo AnagnostouDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Vincent K LamDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Ali H ZaidiAllegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.ORCID 0000-0002-5463-2252
Ronan J KellyThe Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA.
Cynthia L SearsDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-4059-1661
Funding
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science CenterUG1CA233259 · NCI · EMORY UNIVERSITY · PI CARBONE, DAVID P., LEAL, TICIANA · 2019 to 2025
$5.1MLarge-Scale Genetic Analyses of Human CancerR01CA121113 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, VELCULESCU, VICTOR E. · 2006 to 2022
$4.3MImmunogenomic determinants of response and resistance to neoadjuvant anti-PD-1 in resectable NSCLCR37CA251447 · NCI · JOHNS HOPKINS UNIVERSITY · PI Kellie Nicole Smith · 2021 to 2026
$2.2MMetabolite driven mechanisms by which gut microbes impact checkpoint inhibitor success in non-small cell lung cancer patientsK08CA263316 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHAIKH, FYZA Y · 2021 to 2025
$1.1MNCI NIH HHS K08 CA263316NCI NIH HHS R01 CA121113NCI NIH HHS R37 CA251447NCI NIH HHS UG1 CA233259
Abstract
PubMed holds no abstract for this paper.
Indexed as
esophageal cancerfecal microbiomeimmune checkpoint inhibitorsneoadjuvant chemoradiotherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.